Molecule Information

General Information of the Molecule (ID: Mol02081)

• Name: Cysteine desulfurase (K13) ,Plasmodium falciparum
• Synonyms: K13
• Molecule Type: Protein
• Gene Name: K13
• Sequence:
  MKFLQIIKHLKLQNKKNALDNFVNCRTYEHISNINKLFLNNFSSTKEHSEHGQVKHENFL
  NNTLQYGENSQNGSTNNLKNGKYNMYVSEGNVNINEEKYKDNNISSNNTQYNNNSSNSGS
  LNDEGPLWKEHIDDVVNENKKKKMNRFYLDSQATTMIDPRVLDKMLPYMTYIYGNAHSRN
  HFFGWESEKAVEDARTNLLNLINGKNNKEIIFTSGATESNNLALIGICTYYNKLNKQKNH
  IITSQIEHKCILQTCRFLQTKGFEVTYLKPDTNGLVKLDDIKNSIKDNTIMASFIFVNNE
  IGVIQDIENIGNLCKEKNILFHTDASQAAGKVPIDVQKMNIDLMSMSGHKLYGPKGIGAL
  YIKRKKPNIRLNALIHGGGQERGLRSGTLPTHLIVGFGEAAKVCSLEMNRDEKKVRYFFN
  YVKDYLTKHLDYIVFNGCQINRYYGNMNISFLFVEGESLLMSLNEIALSSGSACTSSTLE
  PSYVLRSIGISEDIAHTSIRIGFNRFTTFFEVQQLCINLVKSVERLRSISPLYEME
• Uniprot ID: A0A5J6C8W8_PLAFA

Kingdom: N.A.
Phylum: Apicomplexa
Class: Aconoidasida
Order: Haemosporida
Family: Plasmodiidae
Genus: Plasmodium
Species: Plasmodium falciparum

Type(s) of Resistant Mechanism of This Molecule

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Artesunate

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Plasmodium falciparum malaria [1]

• Resistant Disease: Plasmodium falciparum malaria [ICD-11: 1F40.1]
• Resistant Drug: Artesunate
• Molecule Alteration: Missense mutation; p.C580Y
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Red blood cells; Blood; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Whole genome sequencing assay
• Experiment for Drug Resistance: Giemsa stain assay
• Mechanism Description: All 63 isolates had the K13(C580Y) marker for artemisinin resistance; 79.4% (50/63) had Pfpm2 amplification. K13 mutations confer artemisinin resistance by dampening hemoglobin endocytosis.

References

• Ref 1: Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia .Clin Infect Dis. 2021 Aug 2;73(3):406-413. doi: 10.1093/cid/ciaa628. 10.1093/cid/ciaa628